Welcome to our dedicated page for ASPEN AEROGELS SEC filings (Ticker: ASPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aspen Aerogels, Inc. filings document the company's aerogel technology business, operating results and material corporate events. Recent Forms 8-K cover quarterly and annual financial results, Regulation FD disclosures, business developments, manufacturing-facility updates, and amendments to the MidCap Loan Facility and related credit-party obligations.
The filing record also includes proxy materials describing governance, board and compensation matters, executive employment arrangements, equity awards and shareholder voting items. Aspen's disclosures connect its capital structure and credit covenants with operations in Energy Industrial and Thermal Barrier products, including PyroThin, Cryogel and Pyrogel applications.
Aspen Aerogels Inc. received an amended Schedule 13G filing from Needham Investment Management L.L.C., Needham Asset Management, LLC and George A. Needham reporting their holdings of the company’s common stock. The reporting group states beneficial ownership of 3,260,800 shares of common stock, representing 3.9% of the outstanding class.
All reported shares are held with shared voting and dispositive power, and no sole voting or dispositive power is reported by any of the filers. The securities are directly owned by advisory clients of Needham Investment Management L.L.C., and each reporting person disclaims beneficial ownership except to the extent of its or his pecuniary interest. The filing notes ownership of 5 percent or less of the class.
A shareholder of ASPN filed to sell common stock under Rule 144 through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing covers 5,593 common shares with an aggregate market value of $35,291.83 to be sold on the NYSE.
The shares derive from restricted stock issued by the company, including 3,761 shares from a grant dated 09/13/2025 and 1,832 shares from a grant dated 03/05/2026. These entries are listed as securities to be sold, not new issuances.
Aspen Aerogels, Inc. reported significantly lower results for the quarter and six months ended June 30, 2026. Revenue declined to $49.8 million in Q2 and $87.7 million year‑to‑date, from $78.0 million and $156.7 million in the prior‑year periods, with both Thermal Barrier and Energy Industrial sales down.
Gross profit fell to $3.3 million for Q2 and $7.5 million year‑to‑date, and the company recorded net losses of $23.3 million in Q2 and $47.0 million for the first half, narrower than the prior year, which included large Statesboro plant impairment charges.
At June 30, 2026, Aspen held $151.7 million of cash and cash equivalents, generated $17.9 million of operating cash in the first half, and carried a $79.5 million term loan and $10.9 million drawn on its revolving facility. A $37.6 million settlement with a large Thermal Barrier customer is being recognized as revenue over about two years, contributing to $35.3 million of deferred revenue. The company also booked an $8.9 million loss on damaged assets and a matching insurance receivable from East Providence incidents, and stated that existing cash should support operations for at least twelve months, while long‑term growth is expected to require additional financing.
Aspen Aerogels reported second quarter 2026 revenue of $49.8 million, down from $78.0 million a year earlier, as Thermal Barrier and Energy Industrial sales declined year-over-year amid changes to North American EV regulatory frameworks. Thermal Barrier revenue was $29.5 million versus $55.2 million, while Energy Industrial revenue was $20.4 million versus $22.8 million. Net loss widened to $23.3 million (or $0.28 per share) from $9.1 million (or $0.11 per share), and Adjusted EBITDA moved to a loss of $(6.6) million from a profit of $9.7 million.
Results reflected an $8.9 million loss on property damage from the April 2026 East Providence incident, offset by an equal insurance recovery receivable, plus $5.3 million of other incident-related costs that Aspen plans to claim under business interruption coverage. Despite this disruption, total revenue grew 32% quarter-over-quarter and Thermal Barrier revenue increased 81% quarter-over-quarter, supported by stabilizing North American EV demand and European momentum. The company highlighted a PyroThin® award from Jaguar Land Rover for two next-generation vehicle architectures and ended the quarter with $153.4 million in cash, cash equivalents and restricted cash. For Q3 2026, Aspen guides to revenue of $65–$80 million, net loss of $6–$9 million, and positive Adjusted EBITDA of $7–$15 million, excluding an estimated $5–$10 million of additional incident-related costs.
Aspen Aerogels director William P. Noglows reported an option exercise and updated his holdings. He exercised stock options covering 14,799 shares of Common Stock at an exercise price of $4.75 per share, converting them into directly held shares.
After the transaction, he directly holds 114,156 shares of Common Stock, which the footnotes state includes 103,786 shares and 10,370 Restricted Stock Units. The filing also notes 10,000 shares held indirectly in a trust for each of two children, where he serves as trustee.
Aspen Aerogels, Inc. reported several corporate updates, including leadership, compensation, governance and operations. The board named CFO and Treasurer Grant Thoele as principal accounting officer, succeeding the prior chief accounting officer, and increased his annual base salary to $425,000 effective April 1, 2026, while keeping his 2026 target bonus at 60% of salary.
The company’s annual meeting reached a strong quorum, with 70,437,282 of 82,825,603 eligible shares present, and stockholders re-elected two Class III directors, approved executive compensation, and supported holding say-on-pay votes every year. Stockholders also approved the equity compensation plan and ratified the independent auditor.
Operationally, Aspen announced the initiation of a staged restart of its East Providence, Rhode Island manufacturing facility after an April 8 incident, following comprehensive mechanical, operational and safety reviews with multiple government agencies. The company plans a cautious, phased production ramp and notes that fully restoring the plant’s capabilities will take time, while it continues to investigate the incident and leverage external manufacturing partners.
Aspen Aerogels director Steven R. Mitchell received new equity awards as part of his non-employee director compensation. He was granted 10,370 Restricted Stock Units, each representing one share of common stock upon vesting. These RSUs vest on the earlier of May 13, 2027 or the day before the 2027 annual stockholders meeting.
Mitchell was also granted stock options for 8,706 shares of common stock at an exercise price of $5.40 per share, expiring on May 13, 2036. After these awards, he holds 156,898 common shares and RSUs in total, reflecting routine compensation-related acquisitions rather than open-market purchases.
Aspen Aerogels director James E. Sweetnam received new equity awards. He was granted 10,370 Restricted Stock Units as part of his annual compensation for service as a non-employee director. Each RSU converts into one share of common stock upon vesting in 2027.
He also received stock options for 8,706 shares of common stock at an exercise price of $5.40 per share, expiring on May 13, 2036. Following these awards, he holds 36,321 shares of common stock, including 10,370 RSUs.
Aspen Aerogels director William P. Noglows reported new equity awards and updated holdings. He received 10,370 Restricted Stock Units as part of his annual non-employee director grant, each RSU equal to one common share upon vesting. These RSUs vest on the earlier of May 13, 2027 or the day before the 2027 annual stockholder meeting. He was also granted stock options for 8,706 shares of common stock at an exercise price of $5.40 per share, expiring on May 13, 2036, with the same vesting schedule. After these grants, he directly holds 99,357 common-related units, consisting of 88,987 shares and 10,370 RSUs, and indirectly oversees 10,000 shares in each of two separate trusts for his children.
ASPEN AEROGELS INC director equity grant: Non-employee director Kathleen Kool received 10,370 Restricted Stock Units (RSUs) and options for 8,706 shares of Common Stock as part of her annual equity compensation. The RSUs and options will vest on the earlier of May 13, 2027 or the day before the company’s 2027 annual stockholders meeting. Following the RSU grant, she holds 34,323 shares of Common Stock in total, including 23,953 actual shares and 10,370 RSUs, and 8,706 stock options with a $5.40 exercise price expiring in 2036.